RNS Number : 3839J
OptiBiotix Health PLC
24 October 2024

OptiBiotix Health plc
("OptiBiotix" or the "Company" or "the Group")

Total Voting Rights

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare confirms that its issued share capital and total voting rights is 97,943,161.

This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to issue a notification of their interest in, or of a change in their interest in the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

The Company is aware that an invalid allotment of 3,125,000 shares ("Invalid Allotment Shares") was entered onto its register in August 2024. This allotment was made as a result of an administrative error by the Company. The Company is in the process of correcting this error. The Invalid Allotment Shares have not been notified to the market nor have they been admitted to trading on AIM.

For further information, please contact: OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman *Contact via Walbrook below*
Stephen O'Hara, Chief Executive

Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti

Peterhouse Capital Limited (Broker) Tel: 020 7220 9797
Duncan Vasey / Lucy Williams

Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRBCBDGIXDDGSX